Previous 10 | Next 10 |
ROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer, today announced that it has been granted an award, in the form of an investment of up to app...
ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and nuerodegenerative diseases, today announced that it presented the scientific rationale and design of its...
Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease ROCHESTER, N.Y., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), ...
Vaccinex (NASDAQ: VCNX ): Q3 GAAP EPS of -$0.56 beats by $0.10 . More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019 Updated interim data from the CLASSICAL-Lung study at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Mee...
ROCHESTER, N.Y., Nov. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim data of the Phase 1b/2 study of pepine...
GERMANTOWN, Md., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH Gl...
Updated data from a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating the combination of Vaccinex's (NASDAQ: VCNX ) lead candidate pepinemab and Pfizer (NYSE: PFE ) and Merck KGaA's ( OTCPK:MKGAF ) Bavencio (avelumab) in patients with treatment-resistant advanced non-small cel...
ROCHESTER, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim data of the Phase 1b/2 study of pepin...
ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that Maurice Zauderer, PhD, President and Chief Executive ...
News, Short Squeeze, Breakout and More Instantly...
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, I...
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. Sentine...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...